Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.
NANOMED-Research Center on Nanomedicine and Pharmaceutical Nanotechnology, University of Catania, 95125 Catania, Italy.
Molecules. 2024 Oct 3;29(19):4689. doi: 10.3390/molecules29194689.
Multiple sclerosis (MS) is an immune-mediated demyelinating disease of the nervous system that leads to neurological dysfunctions and severe disabilities. It is worth noting that conventional pharmacotherapy is poorly selective and causes toxicity problems and several systemic side effects. Thus, there is a need to develop new approaches to this medical challenge. The use of nanocarriers for drug delivery represents a good strategy to overcome several issues such as high therapeutic drug doses with side effects, such as diarrhea, nausea, and abdominal pain, and drug degradation processes; in addition, nanocarriers can provide controlled and targeted drug release. This review describes the application of liposomes for the delivery of pharmaceutical actives to target MS. Firstly, MS is explained. Then, liposomes are described along with their preparation, characterization, and stability. The literature about the use of liposomes for the treatment of MS is then analyzed.
多发性硬化症（MS）是一种免疫介导的神经系统脱髓鞘疾病，可导致神经功能障碍和严重残疾。值得注意的是，传统的药物疗法选择性差，会引起毒性问题和多种全身副作用。因此，需要开发针对这一医学挑战的新方法。纳米载体用于药物递送代表了克服许多问题的良好策略，例如具有副作用的高治疗药物剂量，如腹泻、恶心和腹痛以及药物降解过程；此外，纳米载体可以提供控制和靶向药物释放。本文综述了脂质体在将药物活性物质递送至多发性硬化症靶点中的应用。首先，对多发性硬化症进行了解释。然后，描述了脂质体及其制备、表征和稳定性。接着分析了关于脂质体用于治疗多发性硬化症的文献。
